This Glasgow Biotech Just Raised $46M to Take on a Silent Kidney Killer

Jan de Vries · 2026-08-07

A biotech company you've probably never heard of just landed a serious war chest to fight one of the most common—and most overlooked—genetic diseases out there. Mironid, based in Glasgow, Scotland, closed a $46 million Series B round to push its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. That's a big deal for the roughly 12 million people worldwide living with this condition. ### What Is ADPKD, Anyway? ADPKD is the most common hereditary kidney disorder, and it's a nasty one. It's caused by mutations in the PKD1 or PKD2 genes, which lead to the uncontrolled growth of fluid-filled cysts in the kidneys. Over time, these cysts can crowd out healthy tissue, and about half of all patients end up with kidney failure by age 60. That means dialysis or a transplant—not exactly a picnic. Mironid's approach is different from what's currently out there. Instead of just managing symptoms, the company is targeting cyclic AMP (cAMP), a cellular signal that's active at every stage of the disease. By blocking this signal, their LoAc molecules aim to stop new cysts from forming and halt the growth of existing ones. Preclinical data shows the approach reduces cyst number and kidney volume, with a safety profile that looks favorable compared to existing therapies. ### Who's Backing This? The round was led by the Scottish National Investment Bank, with participation from a solid syndicate of existing investors, including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. That's a strong vote of confidence from both public and private players. Neil Wilkie, Mironid's CEO, put it plainly: "Securing funding from such a high-calibre syndicate is a strong validator of our approach." He's right. When a group like that writes checks, it's not just about the money—it's about the signal it sends to the rest of the industry. ### The Science Behind the Hype Mironid wasn't born yesterday. The company spun out of the University of Strathclyde and Heriot-Watt University in 2015, building on over three decades of research into PDE biology by Professor Miles Houslay. That's a long runway of foundational science, which is exactly what you want when you're tackling something as complex as a genetic kidney disease. The pipeline doesn't stop at ADPKD either. Mironid is also targeting phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways tied to inflammatory diseases and cancer. So while this round is about ADPKD, the platform could have legs beyond that. ### What's Next? The fresh capital will go toward advancing the clinical development of Mironid's first-in-class LoAc candidate. The company's long-term goal is to move its programs through preclinical and clinical trials toward commercialization. That's a multi-year journey, but this funding gives them the runway to make real progress. Paul Callaghan, Investment Director at the Scottish National Investment Bank, summed it up well: "Mironid exemplifies Scotland's growing reputation for biotech innovation." And he's not wrong—this is a company that's turning world-class research into something that could genuinely change lives. ### Why You Should Care If you're in the biotech or startup world, this is a reminder that some of the most impactful innovation happens outside the usual hubs. Glasgow isn't Boston or San Francisco, but it's producing companies that can compete on a global stage. And for patients, the potential payoff is huge—a treatment that could slow or stop a disease that currently has no cure. This round follows an earlier Series A extension that brought Mironid's total funding since inception to about $47 million. That's a solid foundation, but the real test will be in the clinic. If the data holds up, this could be a game-changer for kidney disease patients everywhere.